Global Cancer Diagnostics Market to Reach $336.1 Billion by 2030
The global market for Cancer Diagnostics estimated at US$213.8 Billion in the year 2022, is projected to reach a revised size of US$336.1 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2022-2030. Imaging, one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Laboratory Tests segment is readjusted to a revised 4.1% CAGR for the next 8-year period.The U.S. Market is Estimated at $57.1 Billion, While China is Forecast to Grow at 8.9% CAGR
The Cancer Diagnostics market in the U.S. is estimated at US$57.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$77.9 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 5.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.Select Competitors (Total 47 Featured) -
- Abbott Diagnostics
- Abbott Laboratories
- Agilent Technologies, Inc.
- Ambry Genetics Corporation
- Applied Imaging
- AstraZeneca PLC
- AutoGenomics, Inc.
- BARD, A Becton, Dickinson Company
- Bayer AG
- Becton, Dickinson and Company
- BioCurex, Inc.
- bioMeriux SA
- Celara Diagnostics
- Diagnostic Products Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GE Healthcare
- Genoptix, Inc.
- GlaxoSmithKline PLC
- Hologic, Inc.
- Illumina, Inc.
- Pfizer, Inc.
- Philips Healthcare
- QIAGEN GmbH
- Siemens Healthineers
- Thermo Fisher Scientific, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diagnostics
- Abbott Laboratories
- Agilent Technologies, Inc.
- Ambry Genetics Corporation
- Applied Imaging
- AstraZeneca PLC
- AutoGenomics, Inc.
- BARD, A Becton, Dickinson Company
- Bayer AG
- Becton, Dickinson and Company
- BioCurex, Inc.
- bioMeriux SA
- Celara Diagnostics
- Diagnostic Products Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GE Healthcare
- Genoptix, Inc.
- GlaxoSmithKline PLC
- Hologic, Inc.
- Illumina, Inc.
- Pfizer, Inc.
- Philips Healthcare
- QIAGEN GmbH
- Siemens Healthineers
- Thermo Fisher Scientific, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 176 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 213.8 Billion |
Forecasted Market Value ( USD | $ 336.1 Billion |
Compound Annual Growth Rate | 5.8% |
Regions Covered | Global |